Chemical Structure (Rasuvo 01)
Rasuvo Injection, Solution
Product Images NDC 59137-520
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Rasuvo (NDC 59137-520). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medexus Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure A (Rasuvo 02)
RasuV0® is a medication that comes in two strengths: 7.5 mg per 015 mL and 75 mg per 015 mL. The text also includes some illegible characters and an alphanumeric code.*
Figure B (Rasuvo 03)
Rasuvo® is a medication available in a package containing 10mg per 020 mL. It is suitable for men with certain medical conditions. The text also contains a lot of errors and non-English characters, making it difficult to comprehend.*
Figure C (Rasuvo 04)
Figure D (Rasuvo 05)
Not available. The text contains only a mix of gibberish, alphanumeric codes, and symbols that are difficult to understand and do not form coherent phrases or sentences.*
Figure E (Rasuvo 06)
Rasuvo is a medication that comes in a pre-filled syringe containing 17.5 mg per 0.35 mL. The medication is primarily used to treat rheumatoid arthritis. The text also includes various alphanumeric codes, numbers, and symbols that are not comprehensible.*
Figure F (Rasuvo 07)
Figure G (Rasuvo 08)
RasuVvo is a drug with 22.5 mg per 0.45 mL. The package has some details in it, but most of it is not readable.*
Figure H (Rasuvo 09)
Principal Display Panel (7.5 mg Auto-Injector Carton)
This is a not-available result. The scanned text is incomplete, and the output contains mostly gibberish and some fragmented text phrases.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
